Back to Search Start Over

Icariin Alleviates IL-1β-Induced Matrix Degradation By Activating The Nrf2/ARE Pathway In Human Chondrocytes.

Authors :
Zuo S
Zou W
Wu RM
Yang J
Fan JN
Zhao XK
Li HY
Source :
Drug design, development and therapy [Drug Des Devel Ther] 2019 Nov 21; Vol. 13, pp. 3949-3961. Date of Electronic Publication: 2019 Nov 21 (Print Publication: 2019).
Publication Year :
2019

Abstract

Objective: Osteoarthritis (OA) is characterized by progressive matrix destruction of articular cartilage. This study aimed to investigate the potential antioxidative and chondroprotective effects and underlying mechanism of Icariin (ICA) in interleukin-1 beta (IL-1β)-induced extracellular matrix (ECM) degradation of OA cartilage.<br />Methods: Human chondrocyte cell line HC-A was treated with different doses of ICA, and then MTT assay and PI staining were used to estimate ICA-induced chondrocyte apoptosis. Intracellular ROS and superoxide dismutase (SOD) and glutathione peroxidase (GPX) were measured after treatment by IL-1β with or without ICA. The mRNA and protein expression levels of redox transcription factor Nrf2 and the downstream effector SOD-1, SOD-2, NQO-1 and HO-1 were assayed to explore the detailed mechanism by which ICA alleviates ECM degradation. Finally, to expound the role of Nrf2 in ICA-mediated chondroprotection, we specifically depleted Nrf2 in human chondrocytes and then pretreated them with ICA followed by IL-1β.<br />Results: ICA had no cytotoxic effects on human chondrocytes and 10 <superscript>-9</superscript> M was selected as the optimum concentration. ROS induced by IL-1β could drastically activate matrix-degrading proteases and ICA could significantly rescue the matrix degradation and excess ROS generation caused by IL-1β. We observed that ICA activated the Nrf2/ARE pathway, consequently upregulating the generation of GPX and SOD. Ablation of Nrf2 abrogated the chondroprotective and antioxidative effects of ICA in IL-1β-treated chondrocytes.<br />Conclusion: ICA alleviates IL-1β-induced matrix degradation and eliminates ROS by activating the Nrf2/ARE pathway.<br />Competing Interests: The authors declare no conflicts of interest in this work.<br /> (© 2019 Zuo et al.)

Details

Language :
English
ISSN :
1177-8881
Volume :
13
Database :
MEDLINE
Journal :
Drug design, development and therapy
Publication Type :
Academic Journal
Accession number :
31819369
Full Text :
https://doi.org/10.2147/DDDT.S203094